Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Penny Burcham

Nurse Practitioner, Family Oxford, MS Nurse Practitioner

NPI 1609967520 CMS profile 10842229

2908 S Lamar Blvd Ste 100, Oxford, MS 38655

Open in the dashboard

General payments

$22,042

1,273 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Penny Burcham of Oxford, MS is reported in the CMS Open Payments database as having received $22,042 across 1,273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,733 238
2024 General $4,916 239
2023 General $4,382 244
2022 General $4,214 292
2021 General $3,798 260

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Penny Burcham
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Penny Burcham were reported at $4,733. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Penny Burcham Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,798 $124 $35–$379 $132
2022 $4,214 $141 $44–$430 $149
2023 $4,382 $154 $49–$476 $160
2024 $4,916 $165 $51–$504 $164
2025 $4,733 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,672 201 payments
  2. Novartis Pharmaceuticals Corporation $1,329 90 payments
  3. Pfizer Inc. $1,287 86 payments
  4. Amgen Inc. $1,208 89 payments
  5. Jazz Pharmaceuticals Inc. $1,188 53 payments
  6. UCB, Inc. $1,032 43 payments
  7. Alexion Pharmaceuticals, Inc. $956 41 payments
  8. Lilly USA, LLC $906 51 payments
  9. Biogen, Inc. $901 53 payments
  10. SK Life Science, Inc. $790 34 payments
  11. Other $9,774 532 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $21,860 1,269 payments
  2. Education $183 4 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,211 101 payments
  2. AIMOVIG $1,100 83 payments
  3. NURTEC ODT Pain $1,060 71 payments
  4. QULIPTA $1,053 79 payments
  5. XYWAV $894 38 payments
  6. KESIMPTA $737 50 payments
  7. NUPLAZID $707 41 payments
  8. NURTEC ODT Primary Care $690 49 payments
  9. ULTOMIRIS $592 25 payments
  10. EMGALITY $548 35 payments
  11. Other $14,604 801 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

4,653

Median for Nurse Practitioner: 389

Drug cost

$1,658,665

Median for Nurse Practitioner: $21,885

Branded share of claims

25.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sodium Oxybate Generic 12 $229,281
Epidiolex Cannabidiol (Cbd) Brand 28 $221,264
Xywav Sodium,calcium,mag,pot Oxybate Brand 11 $184,538
Kesimpta Pen Ofatumumab Brand 13 $110,383
Aimovig Autoinjector Erenumab-Aooe Brand 117 $97,481
Vumerity Diroximel Fumarate Brand 11 $91,246
Austedo Deutetrabenazine Brand 14 $88,248
Nurtec Odt Rimegepant Sulfate Brand 40 $74,702
Rytary Carbidopa/Levodopa Brand 49 $68,876
Qulipta Atogepant Brand 33 $55,157

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$87,584

Medicare's payments for the services billed

Medicare patients

660

Average age 71

Services billed

2,466

347 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 38%
Ischemic heart disease 38%
Depression 33%
Chronic kidney disease 23%
Atrial fibrillation 20%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
$427 40 —
KESIMPTA
$248 13 —
BOTOX
$248 — —
XYWAV
$244 11 —
ULTOMIRIS
$212 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

1,273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record